{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:03:03Z","timestamp":1780293783698,"version":"3.54.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) patients with bone metastasis-induced paraplegia have an extremely poor prognosis. The potential for neurological recovery following immunotherapy and subsequent rehabilitation in this population remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 58-year-old male with Barcelona Clinic Liver Cancer stage C (BCLC) HCC and T11 vertebral metastasis causing American Spinal Injury Association (ASIA) grade C paraplegia carried a rare POLD1 c.1745C&amp;gt;T (p.T582M) germline mutation with low tumor mutational burden (TMB) and microsatellite instability-low status (MSI-L, blood-based MSI-L (bMSI-L) 7.76%). Immunotherapy with atezolizumab (1200 mg every 3 weeks [Q3W]) combined with targeted therapy with bevacizumab (600 mg Q3W) was initiated in July 2021.A substantial temporal gap of approximately 21 months followed, after which electroacupuncture-based rehabilitation (5-Hz continuous-wave, stimulating Jiaji acupoints, Zusanli, etc) was started in May 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following three months of targeted immunotherapy, the tumor exhibited complete response (CR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST). At the 28-month follow-up assessment, the patient was eventually able to walk independently with a walker. Serial cytokine measurements revealed two distinct peaks in IL-1\u03b2, TNF-\u03b1, and IFN-\u03b3 relative to baseline (2021-06-25): an initial rise after immunotherapy initiation (IL-1\u03b2 up 13.7-fold; TNF-\u03b1 up 2.5-fold; IFN-\u03b3 up 33.3-fold) and a second, larger increase during electroacupuncture rehabilitation coinciding with neurological recovery (IL-1\u03b2 up 31.8-fold; TNF-\u03b1 up 7.2-fold; IFN-\u03b3 up 96.1-fold). These observations suggest temporal associations between immune activation and clinical milestones, but causality cannot be established from a single case.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that POLD1 mutation, despite low TMB and MSI-L, may be associated with enhanced sensitivity to immunotherapy in HCC, though the underlying mechanisms require further investigation. Targeted immunotherapy combined with electroacupuncture may influence neural remodeling by modulating a pro-reparative inflammatory microenvironment, which could potentially support functional reconstruction in patients with spinal metastases. However, there is no direct evidence that immunotherapy accelerates neural recovery, and these observations should be interpreted as hypothesis-generating findings requiring rigorous testing in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1776269","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:31:40Z","timestamp":1780291900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Tumor regression and neurological recovery in paraplegia from POLD1-mutated hepatocellular carcinoma treated with targeted immunotherapy and electroacupuncture"],"prefix":"10.3389","volume":"17","author":[{"given":"Xionghao","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajian","family":"Lin","sequence":"additional","affiliation":[{"name":"Shenzhen Xiao Chuanguo Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansu","family":"Wang","sequence":"additional","affiliation":[{"name":"Shenzhen Xiao Chuanguo Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoguang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pain Management and Rehabilitation, Nan\u2019ao People\u2019s Hospital of Dapeng New District","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pain Management and Rehabilitation, Nan\u2019ao People\u2019s Hospital of Dapeng New District","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pain Management and Rehabilitation, Nan\u2019ao People\u2019s Hospital of Dapeng New District","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25960","article-title":"Hepatocellular carcinoma with extrahepatic metastasis","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer-Am Cancer Soc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.7024","article-title":"Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma","volume":"16","author":"Harding","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","article-title":"POLE\/pold1 mutation and tumor immunotherapy","volume":"41","author":"Ma","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified recist (mrecist) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B5","unstructured":"ClinVar [Internet\n          \n          \n          Bethesda (MD\n          National Library of Medicine (US\n          National library of medicine (US)\n          \n          2013"},{"key":"B6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41588-022-01108-w","article-title":"Functional landscapes of pole and pold1 mutations in checkpoint blockade-dependent antitumor immunity","volume":"54","author":"Ma","year":"2022","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600233","article-title":"Beyond proofreading: POLD1 mutations as dynamic orchestrators of genomic instability and immune evasion in cancer","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","article-title":"Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade","volume":"9","author":"Richman","year":"2019","journal-title":"Cell Syst"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"B11","article-title":"Electro-acupuncture promotes neuroplasticity associated with systematic expressions of NTFs in spinal cord transected rats","volume":"10","author":"Wang","year":"2017","journal-title":"Int J Clin Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.04.029","article-title":"Modulation of neurogenesis via neurotrophic factors in acupuncture treatments for neurological diseases","volume":"141","author":"Shin","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100696","article-title":"Manipulation of the inflammatory reflex as a therapeutic strategy","volume":"3","author":"Kelly","year":"2022","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1776269\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:31:43Z","timestamp":1780291903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1776269\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2026.1776269"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1776269","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1776269"}}